Recent Updates
Recently added Catalysts

Antidepressant medication

Phase 3

Depression | Small molecule | Psychiatry |Harvard Bioscience, Inc.|Last Updated: Nov 5, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedCONTROLLEDDMC
Total Trials2
Total Enrollment1,576
FDA Designations
No designations recorded
Clinical trial landscape

Antidepressant medication · 2 trials · 2 indications

Phase 3 2
NCT05944926Improving Outcomes in Depression in Primary Care in a Low Resource SettingDepression
RECRUITING1,500 Analytics
NCT06153004OptimizeD Pilot StudyDepression
COMPLETED76 Analytics
PHASE3RECRUITING
Improving Outcomes in Depression in Primary Care in a Low Resource Setting
DepressionUnlock trial analytics
PHASE3COMPLETED
OptimizeD Pilot Study
DepressionUnlock trial analytics
Study Endpoints
Primary Endpoints
Depression remission
3 months post recruitment

Remission is defined as PHQ-9 total score \< 5. The PHQ-9 is a self-report measure of depressive symptoms in the prior 2 weeks. Items are rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day), with total scores ranging from 0 to 27, where higher scores indicate more severe depressive symptoms. We will dichotomised the total score using the cut-off score of 5.

Feasibility as measured by recruitment rate
3-months

The investigators will assess enrolment rate for eligible participants

Feasibility as measured by retention rate
3-months

The investigators will evaluate retention rates, which are calculated as the ratio of patients who complete the study to the total number of patients enrolled

Feasibility of study assessments
3-months

The investigators will examine adherence rates to study procedures and the barriers to study participation reported by participants over the course of the study.

Acceptability of interventions by participants
3-months

The investigators will assess treatment compliance. For the HAP arm, this will be defined as having completed at least six sessions. For the ADM arm, this will be defined as having completed more than 80% of the recommended 12-week course of antidepressant medication.

Secondary Endpoints
Cost-effectiveness of optimization
3-, 6-, 9-, 12-months post recruitment
Depression severity, as measured by the Patient Health Questionnaire-9 (PHQ-9)
3-, 6-, 9-, 12-months post recruitment
Generalized Anxiety Disorder Assessment (GAD-7)
3-, 6-, 9-, 12-months post recruitment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeHEALTH_SERVICES_RESEARCH
Treatment Arms
ArmTypeDescription
Healthy Activity Program (HAP)EXPERIMENTALHAP is a brief psychological treatment adapted from behavioral activation therapy, an empirically supported psychological treatment recommended by WHO.
Antidepressant medication (fluoxetine)EXPERIMENTALFluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression. It is a routinely used medication and part of the Essential Drug List (EDL) in India.
Antidepressant medication (ADM)EXPERIMENTALFluoxetine is a selective serotonin reuptake inhibitors (SSRIs) and one of the safest medications used to treat depression. It is a routinely used medication and part of the Essential Drug List (EDL) in India.
Interventions
NameTypeDescription
Healthy Activity Program (HAP)BEHAVIORALHAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
Antidepressant medication (fluoxetine)DRUGPatients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
Antidepressant medication (ADM)DRUGPatients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Participants will be adults aged 18 or over of any gender attending one of the selected Primary Health Care Centers with a "diagnosis" of moderate to severe depression based on scores of 10 or above on the Patient Health Questionnaire-9 (PHQ-9). Exclusion Criteria: 1. Women ...

Countries:India
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT05944926studyFirstPostDate: changed